HANSEN GWENN (Chief Scientific Officer) sold 3.4% of their position (4.11K shares) of NURIX THERAPEUTICS, INC. on the open market
Open‑market sale worth $100.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 8/5/2026ACC: 0001817160-26-000015
Officer· Chief Scientific Officer
Since Jul 2020
-4.11K
Net shares
Net seller
$100.1K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.11K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−1.50K
Price / share
$23.87
Trade value
$35.80K
% of position
1.2%
8/4/2026
121.34K→119.84K
Common Stock
Direct
Shares
−2.61K
Price / share
$24.64
Trade value
$64.34K
% of position
2.2%
8/4/2026
119.84K→117.23K
Total
Net shares
−4.11K
Net value
-$100.14K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 8/4/2026 | S · Sale | −1.50K | $23.87 | $35.80K | 1.2% | 121.34K | 119.84K |
| Common Stock Direct | 8/4/2026 | S · Sale | −2.61K | $24.64 | $64.34K | 2.2% | 119.84K | 117.23K |
| Total | −4.11K | -$100.14K | ||||||
Derivative Transactions0
No derivative transactions reported